Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...

Sexual health, personality disorders, incontinence, infertility, addiction, end-of-life care and chronic pain are some of the messy, painful and complicated realities of being human. Too often, people ...

The NHS in 2026 is facing a familiar but intensifying oncology challenge. Our data at HSJ Information shows rising incidence, workforce strain, diagnostic bottlenecks and stark inequalities in ...

The arrival of ChatGPT as a mass consumer tool, available to anyone with a smartphone or a PC in November 2023, heralded a new Armageddon scenario for the global employment market. The fear that ...

For decades, the UK’s pharmaceutical and biotech sectors have been leaders in discovery and innovation. Yet as the cost of bringing innovation to market increases and global competition intensifies, ...

The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...

Bioxytran has announced encouraging results from a randomized, double‑blind, placebo‑controlled phase 1b/2a study of its oral ...

HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in ...

Chief Executive Officer Sean A MacDonald added: “The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative ...

Astellas Pharma has announced that the National Institute for Health and Care Excellence has issued Final Draft Guidance recommending fezolinetant 45 mg once daily for treating moderate to severe ...

UCB has announced positive topline results from its BE BOLD trial, the first head‑to‑head study in active psoriatic arthritis to demonstrate superiority of one licensed biologic therapy over an IL‑23 ...